Table 1.
Baseline patient and disease characteristics
| ODM-203 capsule | ODM-203 tablet | Total | |||||||
| 100 mg | 200 mg | 400 mg | 600 mg | 800 mg | 200 mg | 300 mg | 400 mg | (N=84) | |
| (n=1) | (n=3) | (n=7) | (n=30) | (n=7) | (n=3) | (n=3) | (n=30) | ||
| Mean age, years | 65.0 | 65.0 | 51.0 | 54.1 | 52.3 | 56.3 | 65.0 | 59.7 | 56.7 |
| Female, n (%) | 0 (0.0) | 2 (66.7) | 5 (71.4) | 18 (60.0) | 3 (42.9) | 3 (100) | 2 (66.7) | 21 (70.0) | 54 (64.3) |
| Race, n (%) | |||||||||
| Caucasian | 1 (100) | 3 (100) | 7 (100) | 28 (93.3) | 7 (100) | 1 (33.3) | 3 (100) | 29 (96.7) | 79 (94.0) |
| Black | 0 | 0 | 0 | 1 (3.3) | 0 | 0 | 0 | 1 (3.3) | 2 (2.4) |
| Other | 0 | 0 | 0 | 1 (3.3) | 0 | 2 (66.7) | 0 | 0 | 3 (3.6) |
| Cancer type, n (%) | |||||||||
| Cholangiocarcinoma | – | – | – | – | – | – | – | – | 15 (17.9) |
| Breast cancer | – | – | – | – | – | – | – | – | 9 (10.7) |
| Colorectal cancer | – | – | – | – | – | – | – | – | 9 (10.7) |
| Soft tissue sarcoma | – | – | – | – | – | – | – | – | 7 (8.3) |
| Endometrial cancer | – | – | – | – | – | – | – | – | 5 (6.0) |
| Ovarian cancer | – | – | – | – | – | – | – | – | 5 (6.0) |
| Medullary thyroid cancer | – | – | – | – | – | – | – | – | 5 (6.0) |
| Renal cell carcinoma | – | – | – | – | – | – | – | – | 4 (4.8) |
| Other | – | – | – | – | – | – | – | – | 25 (29.8) |
| ECOG, n (%) | |||||||||
| 0 | 1 (100) | 1 (33.3) | 4 (57.1) | 14 (46.7) | 4 (57.1) | 0 (0.0) | 2 (66.7) | 10 (33.3) | 36 (42.9) |
| 1 | 0 (0.0) | 2 (66.7) | 3 (42.9) | 16 (53.3) | 3 (42.9) | 3 (100) | 1 (33.3) | 20 (66.7) | 48 (57.1) |
ECOG, Eastern Cooperative Oncology Group.